NDLI: The role of health technology assessment bodies in shaping drug development

Content Provider	PubMed Central
Author	Ciani, Oriana Claudio, Jommi
Copyright Year	2014
Abstract	The use of health technology assessment (HTA) to inform policy-making is established in most developed countries. Compared to licensing agencies, HTA agencies have different interests and, therefore, different evidence requirements. Criteria for coverage or reimbursement decisions on pharmaceutical compounds vary; however, it is common to include, as part of the HTA, a comparative effectiveness evaluation. This type of clinical data might go beyond that required for market authorization, thus creating an additional evidence gap between the regulatory and the reimbursement submission. The relevance of submissions to HTA agencies is consistently increasing in a pharmaceutical company’s perspective, as market prospects are strongly influenced by third-party payers’ coverage. In this study, we aim to describe current HTA activities with a potential impact throughout the drug development process of pharmaceuticals, with a comparative emphasis on the systems in place in Italy and in the UK. Based on an extensive literature and website review, we identified three major classes of HTA activities, beyond mainstream HTA, with the potential to influence the drug development program: 1) horizon scanning and early HTA; 2) bipartite and tripartite early dialogue between manufacturers, regulators, and HTA assessors; and 3) managed market entry agreements. From early stages of clinical research up to postauthorization studies, there is a trend toward increased collaboration between parties, anticipation of market access evidence collection, and postmarketing risk-sharing. Heterogeneity of HTA practices increases the complexity of the market access environment. Overall, there are signals that market access departments are gaining importance in the pharmaceutical companies, but there is still a lack of evidence and reporting on how the increasing relevance of HTA has reshaped the way clinical development is designed and managed.
Related Links	http://dx.doi.org/10.2147/dddt.s49935
Ending Page	2281
Page Count	9
Starting Page	2273
File Format	PDF
ISSN	11778881
e-ISSN	11778881
Journal	Drug Design, Development and Therapy
Volume Number	8
Language	English
Publisher	Dove Medical Press
Publisher Date	2014-11-01
Access Restriction	Open
Rights Holder	Dove Medical Press
Subject Keyword	Pharmacology Drug Discovery Pharmaceutical Science Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Drug Discovery Pharmacology Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies

The role of aflibercept in the management of diabetic macular edema

The role of dasatinib in the management of chronic myeloid leukemia

Bioequivalence assessment of two formulations of ibuprofen

Drug discovery and development for neglected diseases: the DNDi model

Daclatasvir: potential role in hepatitis C

The preventive role of transurethral antibiotic delivery in a rat model

Role of short-acting nitroglycerin in the management of ischemic heart disease

Profile of ipilimumab and its role in the treatment of metastatic melanoma

The role of health technology assessment bodies in shaping drug development

Similar Documents

Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies

The role of aflibercept in the management of diabetic macular edema

The role of dasatinib in the management of chronic myeloid leukemia

Bioequivalence assessment of two formulations of ibuprofen

Drug discovery and development for neglected diseases: the DNDi model

Daclatasvir: potential role in hepatitis C

The preventive role of transurethral antibiotic delivery in a rat model

Role of short-acting nitroglycerin in the management of ischemic heart disease

Profile of ipilimumab and its role in the treatment of metastatic melanoma

The role of health technology assessment bodies in shaping drug development